Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 7/20 | 0.63 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.63 |
| ▸ | NQO2 | P16083 | 1/20 | 0.63 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.62 |
| ▸ | AKR1C3 | P42330 | 6/20 | 0.61 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.61 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.61 |
| ▸ | HTR6 | P50406 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2686296 | 0.87 | MTNR1A (0.65) | MTNR1AMTNR1BNQO2ADRB2AKR1C3 | |
| SCHEMBL18509701 | 0.86 | MTNR1A (0.67) | MTNR1AMTNR1BNQO2ADRB2HTR6 | |
| SCHEMBL25100759 | 0.85 | HTR6 (0.62) | MTNR1AMTNR1BNQO2AKR1C3AKR1C2 | |
| SCHEMBL13888101 | 0.83 | ADRB2 (0.70) | MTNR1AMTNR1BNQO2ADRB2AKR1C3 | |
| SCHEMBL24723814 | 0.83 | MTNR1A (0.57) | MTNR1AMTNR1BNQO2ADRB2AKR1C3 | |
| SCHEMBL12480873 | 0.82 | AKR1C3 (0.67) | MTNR1AAKR1C3AKR1C2AKR1C4PTGS1 | |
| SCHEMBL24723269 | 0.82 | MTNR1A (0.56) | MTNR1AMTNR1BNQO2ADRB2AKR1C3 | |
| SCHEMBL16494963 | 0.81 | HTR6 (0.57) | MTNR1AMTNR1BNQO2ADRB2AKR1C3 | |
| SCHEMBL11888513 | 0.81 | CDK2 (0.47) | HSD17B10KDM4E | |
| SCHEMBL2684793 | 0.81 | SPR (0.55) | MTNR1AMTNR1BPTGS1HTR6HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10849841-B2 | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2020-12-01 | — | — | US | disclosed |
| EP-3078374-B1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | UNIV VANDERBILT (US) | 2019-06-19 | — | — | EP | disclosed |
| US-9889082-B2 | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-02-13 | — | — | US | disclosed |
| EP-3175856-A1 | METHODS AND COMPOSITIONS FOR INHIBITING OR REDUCING HAIR LOSS | The Trustees of the University of Pennsylvania (US) | 2017-06-07 | — | — | EP | disclosed |
| EP-3130589-A1 | HETEROCYCLIC AZA COMPOUNDS | Grünenthal GmbH (DE) | 2017-02-15 | — | — | EP | disclosed |
| EP-2037967-B1 | PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS FOR TREATING ANDROGENETIC ALOPECIA | UNIV PENNSYLVANIA (US) | 2016-12-07 | — | — | EP | disclosed |
| US-20160346186-A1 | METHODS AND COMPOSITIONS FOR INHIBITING OR REDUCING HAIR LOSS, ACNE, ROSACEA, PROSTATE CANCER, AND BPH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-12-01 | — | — | US | disclosed |
| EP-2638034-A1 | SUBSTITUTED HETEROAROMATIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012062462-A1 | SUBSTITUTED HETEROAROMATIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012062462-A1 | SUBSTITUTED HETEROAROMATIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2012-05-18 | — | — | WO | disclosed |
| EP-0642513-B1 | INDOLOCARBAZOLE IMIDES AND THEIR USE | KTB TUMORFORSCHUNGSGESELLSCHAF (DE) | 2000-08-09 | — | — | EP | disclosed |
| US-5945440-A | Indolocarbazole imides and the use thereof | GOEDECKE AKTIENGESELLSCHAFT (DE) | 1999-08-31 | — | — | US | disclosed |
| EP-0747379-B1 | Derivatives of indole, indazole and benzisoxazole for the treatment of schizophrenia | ADIR (FR) | 1999-08-11 | — | — | EP | disclosed |
| US-5883114-A | TREATING CANCEROUS TUMORS, INFLAMMATORY DISEASES, AND ALLERGIES | GOEDECKE AKTIENGESELLSCHAFT (DE) | 1999-03-16 | — | — | US | disclosed |
| US-5721245-A | ANTIINFLAMMATORY AGENTS, RESPIRATORY SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1998-02-24 | — | — | US | disclosed |
| EP-0747379-A1 | Derivatives of indole, indazole and benzisoxazole for the treatment of schizophrenia | ADIR ET COMPAGNIE (FR) | 1996-12-11 | — | — | EP | disclosed |
| EP-0642513-A1 | INDOLOCARBAZOLE IMIDES AND THEIR USE | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1995-03-15 | — | — | EP | disclosed |
| EP-0384349-B1 | Substituted pyrroles | HOFFMANN LA ROCHE (CH) | 1994-04-27 | — | — | EP | disclosed |
| WO-1993024491-A1 | INDOLOCARBAZOLE IMIDES AND THEIR USE | Gödecke Aktiengesellschaft (DE) | 1993-12-09 | — | — | WO | disclosed |
| EP-0384349-A1 | Substituted pyrroles | F. HOFFMANN-LA ROCHE AG (CH) | 1990-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160346186-A1 | METHODS AND COMPOSITIONS FOR INHIBITING OR REDUCING HAIR LOSS, ACNE, ROSACEA, PROSTATE CANCER, AND BPH | AR, BPHL, PTGS2 | MTNR1A 405/4885MTNR1B 530/4885NQO2 1434/4885 |
| US-10849841-B2 | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH | AR, BPHL, PTGS2 | MTNR1A 405/4885MTNR1B 530/4885NQO2 1434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.